Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 558 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Fatty Liver, Nonalcoholic Clear all
Completed Phase 2 Interventional Results available

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

NCT02960204
View directory record Official record
Conditions
Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
Interventions
Emricasan, Placebo
Drug
Lead sponsor
Histogen
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
Pasadena, California • Rialto, California • Palmetto Bay, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Effect of Omega-3 PUFA Supplementation in NAFLD Patients

NCT00230113
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish oil, Safflower oil
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

NCT04197479
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
76
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Comparison of Dietary Sugar Reduction Methods

NCT04186793
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Guided Grocery Shopping (GGS), Diet Provision Group
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis

NCT00680407
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Placebo, Silymarin 700 mg, Silymarin 420 mg
Other · Drug
Lead sponsor
Madaus Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 18, 2026, 8:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

NCT00536250
View directory record Official record
Conditions
Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
8 Years to 22 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.

NCT02196051
View directory record Official record
Conditions
Insulin Resistance
Interventions
one bout of 45 minutes exercise
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NCT04857606
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
AMG 609, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • Chula Vista, California • Montclair, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02787304
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Coronado, California • Fresno, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HPG1860, Placebo
Drug
Lead sponsor
Hepagene (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Not yet recruiting Phase 2 Interventional

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

NCT03867487
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
12 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

NCT04132440
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Physician
Interventions
Interview, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Recruiting Phase 2 Interventional

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

NCT06355310
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
16 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated Not applicable Interventional Results available

Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease

NCT04576923
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis
Interventions
Velacur by Sonic Incytes
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 18, 2026, 8:19 AM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Liver - Healthy Brain

NCT05216796
View directory record Official record
Conditions
Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
Interventions
Diet Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

NCT01529268
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
DR cysteamine bitartrate capsule, DR cysteamine bitartrate placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 18, 2026, 8:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

NCT05209100
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Sigmoidoscopy
Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
35 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 18, 2026, 8:19 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481
View directory record Official record
Conditions
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Interventions
Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

NCT04378010
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 1.5 mg, EDP-305 2 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
68
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 18, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NCT04054310
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Liver Multi Scan
Diagnostic Test
Lead sponsor
Perspectum
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Chandler, Arizona • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

NCT03332940
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Interventions
Tc 99M Sulfur Colloid, Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 18, 2026, 8:19 AM EDT